Biotech News
OraSure Announces Third Quarter 2026 Financial Results; Strategic Execution Drives Double-Digit Year-Over-Year Growth and Margin Expansion
14% year-over-year revenue growth in the quarter highlights effectiveness of return-to-growth strategy GAAP gross margin improved by over 170 bps vs. prior year to 45.2% Received initial orders of Colli-Pee®•Dx and OraQuick® Ebola 2.0 in the quarter OTI expects an acceleration of full-year revenue
